close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myovant Sciences Ltd. Common Shares (NY:MYOV)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Mar 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 26.96 (11)
Ask (Size) 27.01 (2,500)
Prev. Close 26.98
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 92,077,860
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
From Myovant Sciences, Inc.
Via GlobeNewswire
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

More News

Read More
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
From Myovant Sciences, Inc.
Via GlobeNewswire
Myovant Sciences: Q2 Earnings Insights
Via Benzinga
Where Myovant Sciences Stands With Analysts
Via Benzinga
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
From Myovant Sciences, Inc.
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Myovant Sciences Ltd. (NYSE - MYOV), ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC),
From Brodsky & Smith LLC
Via GlobeNewswire
Looking Into Myovant Sciences's Return On Invested Capital
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Via Benzinga
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
From Myovant Sciences, Inc.
Via GlobeNewswire
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
From Kahn Swick & Foti, LLC
Via Business Wire
Earnings Outlook For Myovant Sciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Via Benzinga
US Stock Futures Down; Big Tech Earnings In Focus
Via Benzinga
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
Via Benzinga
Myovant Sciences Cancels Second Quarter Earnings Conference Call
From Myovant Sciences, Inc.
Via GlobeNewswire
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BYND Stock Alert: What to Know as Beyond Meat Launches Plant-Based Steak Product
Via InvestorPlace
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Via InvestorPlace
US Stocks Mixed; Dow Jumps 200 Points
Via Benzinga
Why Myovant Sciences Stock Is Moving Higher
Via Benzinga
Tesla Slashes China EV Prices, TSMC Joins Embargo After NVIDIA and AMD, Schlumberger Rebrands As SLB: Top Stories Monday, Oct. 24
Via Benzinga
MYOV STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Myovant Sciences Ltd. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Myovant Sciences Ltd. Common Shares publicly traded?
Yes, Myovant Sciences Ltd. Common Shares is publicly traded.
What exchange does Myovant Sciences Ltd. Common Shares trade on?
Myovant Sciences Ltd. Common Shares trades on the New York Stock Exchange
What is the ticker symbol for Myovant Sciences Ltd. Common Shares?
The ticker symbol for Myovant Sciences Ltd. Common Shares is MYOV on the New York Stock Exchange
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today